United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Diversified Trust Co

Diversified Trust Co lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 69.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 751 shares of the biotechnology company’s stock after selling 1,691 shares during the quarter. Diversified Trust Co’s holdings in United Therapeutics were worth $269,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of UTHR. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new stake in United Therapeutics during the 2nd quarter valued at about $30,000. Rise Advisors LLC purchased a new stake in United Therapeutics during the 1st quarter valued at about $32,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics in the second quarter valued at about $33,000. Finally, Benjamin F. Edwards & Company Inc. raised its position in United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after buying an additional 117 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $328.03, for a total value of $1,180,908.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $42,643.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $328.03, for a total value of $1,180,908.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $42,643.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raymond Dwek sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now owns 1,750 shares in the company, valued at approximately $569,362.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,238 shares of company stock valued at $35,612,493 in the last 90 days. 11.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on UTHR. Jefferies Financial Group boosted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. Wells Fargo & Company boosted their price target on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $400.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

United Therapeutics Stock Up 1.1 %

UTHR opened at $358.22 on Friday. The company has a market cap of $15.94 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 1.30 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The company has a 50-day moving average price of $346.73 and a 200 day moving average price of $303.39. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter last year, the business earned $5.24 EPS. The business’s revenue was up 19.8% compared to the same quarter last year. Sell-side analysts expect that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.